Previous Statements by MYL
» Mylan, Inc. - Analyst/Investor Day
» Mylan's CEO Discusses Q3 2011 Results - Earnings Call Transcript
» Mylan's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Mylan's (MYL) own generic version of the EpiPen should outperform Kaleo's Auvi-Q, due out in 2017, Mizuho's Irina Koffler said.